Spots Global Cancer Trial Database for refractory burkitt lymphoma

Every month we try and update this database with for refractory burkitt lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia	NCT03136146	Recurrent Acute... Recurrent Adult... Recurrent Burki... Recurrent Burki... Recurrent Child... Recurrent High ... Refractory Acut... Refractory Burk... Refractory Burk... Refractory High... Refractory Lymp...	Bortezomib Clofarabine Cyclophosphamid... Dexamethasone Etoposide Ofatumumab Pegfilgrastim Rituximab Vincristine Sul...	15 Years -	M.D. Anderson Cancer Center
Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	NCT04285268	High Grade B-Ce... Recurrent Burki... Recurrent Diffu... Recurrent High ... Refractory Burk... Refractory Diff... Refractory High...	Bortezomib Rituximab Venetoclax	18 Years -	Rutgers, The State University of New Jersey
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	NCT02992522	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Margi... Refractory Burk... Refractory Diff... Refractory Foll... Transformed Rec... B-Cell	Lenalidomide Obinutuzumab Venetoclax	18 Years -	Ohio State University Comprehensive Cancer Center
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	NCT02568553	Recurrent Burki... Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Gray-... Recurrent Mantl... Recurrent Margi... Recurrent Media... Recurrent Non-H... Recurrent Small... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Gray... Refractory Mant... Refractory Marg... Refractory Medi... Refractory Non-... Refractory Smal...	Blinatumomab Lenalidomide	18 Years -	National Cancer Institute (NCI)
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	NCT01897012	MYC Positive Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent High ... Recurrent Hodgk... Recurrent Mantl... Recurrent Matur... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory High... Refractory Hodg... Refractory Mant... Refractory Matu...	Alisertib Laboratory Biom... Romidepsin	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	NCT02950220	B-Cell Lymphoma... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Mediastinal Lym... Recurrent B-Cel... Recurrent Burki... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Walde... Refractory B-Ce... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant...	Ibrutinib Laboratory Biom... Pembrolizumab	18 Years -	Ohio State University Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: